Figure 1.
(A) Continuous glucose monitoring system on subcutaneous insulin: HbA1c 9.2%; dose increases resulted in recurrent hypoglycemia. (B) Same patient on a continuous glucose monitoring system 3 months after initiation of CSII: HbA1c 6.6%.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.